LivaNova PLC (LIVN) Stock
LIVN has an Alpha Score of 63 out of 100 (moderate), computed on Nov 9, 2026 from 3 of 4 sub-scores. Company insiders reported 0 open-market buys and 3 sales on SEC Form 4 in the 90 days to Nov 6, 2026. Its trailing P/E ratio is 26.8 and its net margin 12.8% (key statistics as of Nov 10, 2026).
What is LIVN's Alpha Score?
How it works →Alpha Score of 63 reflects moderate overall profile with strong momentum, weak value, moderate quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 9, 2026
A rules-based research rating, not a recommendation to buy or sell.
Are LivaNova PLC insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 10, 26 | Bianchi Francesco | Director | SELL | 3.5K | $273K |
| Sep 4, 26 | Story Brooke | Director | SELL | 2.3K | $187K |
| Aug 31, 26 | Bianchi Francesco | Director | SELL | 1.6K | $132K |
| Aug 11, 26 | Tezel Ahmet | Chief Innovation Officer | SELL | 2.7K | $208K |
SEC Form 4 filings as of Nov 6, 2026 · not updated for 4 days; newer filings may exist
See cluster-buy signals across all tickers →What are LIVN's key statistics?
Key statistics as of Nov 10, 2026
How does LIVN's valuation compare with the Healthcare sector?
| Metric | LIVN | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 26.8 | 29.7 | 114 |
| Net margin | 12.81% | 3.62% | 174 |
| Return on equity | 15.41% | 2.96% | 200 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 10, 2026). P/E excludes loss-making companies.
LIVN price chart
Powered by TradingViewWhat does LivaNova PLC do?
LivaNova is a global medical technology company that develops innovative devices and therapies for cardiac surgery, cardiopulmonary support, and neuromodulation treatments. The company's primary product portfolio includes vagus nerve stimulation therapy for drug-resistant epilepsy and difficult-to-treat depression, along with advanced cardiopulmonary solutions for cardiac surgical procedures. LivaNova serves healthcare providers and patients worldwide, addressing critical medical needs in neurology and cardiovascular care. Established through the 2015 merger of Cyberonics and Sorin, the company combines decades of expertise in both neuromodulation and cardiopulmonary innovation. Operating through specialized business units headquartered in different regions, LivaNova also maintains a digital health initiative focused on epilepsy treatment support. The company is headquartered in London and employs thousands of professionals dedicated to transforming patient outcomes through advanced medical technology solutions.